Critical Path Institute® (C-Path) has revealed significant leadership changes, promoting Diane Stephenson, Ph.D., to the position of Vice President of Neurology, while also appointing Nadine Tatton, Ph.D., as the new Executive Director of the Critical Path for Alzheimer’s Disease (CPAD) Consortium.
Dr. Stephenson has dedicated over 30 years to specialized research in neuroscience and drug development. Notably, she has spent nearly 15 years as the Executive Director of the Critical Path for Parkinson’s Consortium (CPP) and has played a pivotal role in advancing our understanding of debilitating neurodegenerative diseases, including Alzheimer’s (AD) and Parkinson’s (PD). Her collaborative leadership has significantly broadened treatment pathways and enhanced scientific insights across the field.
As the newly appointed Vice President of Neurology, Dr. Stephenson will guide C-Path’s initiatives aimed at fostering brain health, leveraging her extensive expertise in neuroimaging, neuropathology, digital health technologies, and translational model characterization. Furthermore, she will maintain her critical role as Executive Director of CPP, ensuring the strategic alignment of these initiatives with C-Path’s overarching mission.
It is a great privilege to advance my career at C-Path, an organization at the forefront of developing treatments for neurodegenerative diseases. I am looking forward to this new chapter, where I will continue to build upon our collective expertise across academia, industry, and regulatory bodies to deepen our impact on patient care.”
Diane Stephenson, Ph.D., Vice President of Neurology
Dr. Nadine Tatton comes to C-Path with extensive experience exceeding two decades in drug development and research of neurodegenerative diseases. She possesses a Ph.D. in physiology (neuroscience) from the University of Toronto, supplemented by postdoctoral studies in spinal cord research and molecular neuroscience. Throughout her career, Dr. Tatton has taken on several leadership roles within both academic and industry settings, specifically targeting clinical advancements for diseases including Alzheimer’s, frontotemporal dementia (FTD), and Parkinson’s disease.
Before moving to C-Path, Dr. Tatton was the Medical Director of Immuno-Neurology at Alector, Inc., contributing to groundbreaking therapeutic strategies aimed at neurodegenerative conditions. Notably, her tenure as Scientific Director at the Association for Frontotemporal Degeneration allowed her to initiate collaborative partnerships that propelled research focused on FTD disorders and helped establish the FTD Disorders Registry. This diverse professional background uniquely positions her to lead CPAD in fostering innovative regulatory science, crucial for accelerating drug development for AD.
“I am honored to join C-Path and to lead the CPAD Consortium in its mission to drive therapeutic innovation for Alzheimer’s disease,” expressed Dr. Tatton. “There is so much momentum in AD research today, and I look forward to collaborating with our global partners across various sectors to explore what can be achieved in Alzheimer’s drug development.”
C-Path CEO, Klaus Romero, M.D., M.S., FCP, expressed enthusiasm regarding the recent leadership appointments. He stated, “Dr. Stephenson’s promotion aligns perfectly with C-Path’s strategic objectives to enhance our collaborative approach aimed at fostering innovation in tools that will expedite drug development for neurodegenerative diseases. Dr. Tatton’s leadership at CPAD will empower C-Path to unveil new initiatives and fortify our foundational capabilities in data-driven collaboration for swift drug development in Alzheimer’s. Their leadership is vital as we work toward addressing the pressing challenges within neurodegenerative research.”
Both appointments take effect immediately, as Drs. Stephenson and Tatton commit to their pivotal roles in advancing research focused on neurology, particularly surrounding Parkinson’s and Alzheimer’s diseases, with a crucial emphasis on patient-centered approaches.
Source:
Leadership Changes at Critical Path Institute: A Move Towards Neurodegenerative Research
Well, folks, put down your cheese toasties and gather ’round the news—the Critical Path Institute (C-Path) has just shaken things up in the world of neurology! C-Path has announced some key leadership appointments that are undoubtedly going to make waves in the neurodegenerative disease sector. We’ve got Dr. Diane Stephenson taking a big leap into the role of Vice President of Neurology, and let’s not forget the delightful Dr. Nadine Tatton stepping in as the new Executive Director of the Critical Path for Alzheimer’s Disease (CPAD) Consortium. It’s like the Avengers, but for brains!
Meet the Superheroes
Dr. Stephenson is no newbie; she’s got over 30 years of experience. I mean, she’s spent almost 15 years running the Critical Path for Parkinson’s Consortium (CPP). That’s nearly as long as some of my relationships! She’s been crucial in drawing the map for neurodegenerative diseases like Alzheimer’s and Parkinson’s—sort of like Google Maps, but with fewer detours to the bathroom.
From neuroimaging to digital health technologies, Dr. Stephenson has her finger on the pulse of brain research like it’s the one song that just won’t get out of her head. And don’t you worry, she’s not leaving CPP in the lurch; she’ll still have one foot in both camps, ensuring that our minds are in tip-top condition. Talk about multitasking!
“It is a great privilege to advance my career at C-Path, an organization at the forefront of developing treatments for neurodegenerative diseases. I am looking forward to this new chapter, where I will continue to build upon our collective expertise across academia, industry, and regulatory bodies to deepen our impact on patient care.”
— Diane Stephenson, Ph.D., Vice President of Neurology
The New Kid on the Block: Dr. Nadine Tatton
Now for the grand entrance of Dr. Nadine Tatton—what a résumé! She’s got over two decades of experience, most notably, she’s worked on the cutting edge of neurodegenerative disease research like a chef preparing the next Michelin-star dish of brain health studies. You might say she has a Ph.D. in “let’s get this brain research moving!”
With a history as the Medical Director at Alector, Inc., she’s been cooking up novel therapies that aim to save our cognitive faculties. Her work at the Association for Frontotemporal Degeneration sounds like something out of a superhero origin story, where she turned collaboration into an art form to advance research on frontotemporal dementia (FTD). Building registries? Oh, honey, that’s just Tuesday for Dr. Tatton!
“I am honored to join C-Path and to lead the CPAD Consortium in its mission to drive therapeutic innovation for Alzheimer’s disease. There is so much momentum in AD research today, and I look forward to working with our global collaborators across industry, regulatory agencies, and academia to push the boundaries of what is possible in Alzheimer’s drug development.”
— Nadine Tatton, Ph.D., Executive Director of CPAD
From the Horse’s Mouth: C-Path CEO Klaus Romero
C-Path CEO Klaus Romero must be feeling like a kid in a candy store! In a delightful chat about the new appointments, he noted how Dr. Stephenson’s promotion aligns with their strategy of a collaborative approach. That’s corporate speak for “let’s all hold hands and figure this brain stuff out together.” He emphasized the importance of their leadership, saying it’s crucial as they delve into the vast ocean of neurodegenerative research and aim to address the unmet challenges therein.
The Big Picture
Both of these appointments are effective immediately, meaning they won’t waste a moment in their quest for brain health victories. It’s an exciting time—a bit like a sci-fi movie where the heroes come together just when the world needs them the most. With Dr. Stephenson and Dr. Tatton at the helm, you’d better believe that advances in Alzheimer’s and Parkinson’s research are on the horizon.
So, readers, keep your eyes peeled and your minds open. The world of neurodegenerative diseases is about to become a whole lot more interesting. Let’s raise a glass—or perhaps a few neurons—to innovation, collaboration, and a future where brain health becomes a top priority. Cheers to brainpower!
**Interview with Dr. Klaus Romero, CEO of C-Path**
**Interviewer:** Thank you for joining us today, Dr. Romero. It’s an exciting time for the Critical Path Institute with the recent leadership changes. Can you tell us more about the appointments of Dr. Diane Stephenson and Dr. Nadine Tatton?
**Dr. Klaus Romero:** Thank you for having me! Indeed, we’re thrilled about these appointments. Dr. Stephenson, with her deep expertise in neuroscience and her extensive experience leading the Critical Path for Parkinson’s Consortium, will be instrumental as our new Vice President of Neurology. She has an exceptional track record in advancing research that can translate into new treatments for neurodegenerative diseases.
**Interviewer:** And what about Dr. Tatton? What do you foresee as her contributions to C-Path?
**Dr. Klaus Romero:** Dr. Tatton brings over two decades of invaluable experience in neurodegenerative research. Her leadership in the CPAD Consortium will be vital as we strive to foster innovation, especially regarding Alzheimer’s. Her collaborative approach is something we highly value, and her previous work in establishing partnerships to propel research is directly aligned with C-Path’s mission.
**Interviewer:** Collaboration seems at the heart of C-Path’s strategy. How will these appointments enhance your collaborative efforts in drug development?
**Dr. Klaus Romero:** Absolutely. Both Dr. Stephenson and Dr. Tatton have proven that collaboration yields significant scientific advancements. Their combined expertise across academia, industry, and regulatory bodies will allow C-Path to enhance its data-driven collaborations, which is crucial for the swift development of drugs to combat neurodegenerative diseases like Alzheimer’s and Parkinson’s.
**Interviewer:** Dr. Stephenson mentioned enhancing patient care in her remarks. How do you plan to ensure that these new initiatives are patient-centered?
**Dr. Klaus Romero:** That’s a fundamental priority for us. We believe that every advancement in drug development should ultimately lead to improved patient outcomes. By aligning our initiatives with patient-centric approaches, we aim to not only expedite treatments but also ensure that they meet the specific needs of those affected by neurodegenerative diseases.
**Interviewer:** As you move forward, what are your main goals for C-Path in the coming months?
**Dr. Klaus Romero:** Our main goal is to enhance our capabilities in regulatory science and innovation for drug development. We recognize the urgency in addressing challenges within the neurodegenerative research landscape. With the leadership of Dr. Stephenson and Dr. Tatton, we are poised to make significant strides in this area, ultimately benefiting patients and the broader medical community.
**Interviewer:** Thank you for your insights, Dr. Romero. It’s an exciting time for C-Path, and I look forward to seeing the impact of these changes.
**Dr. Klaus Romero:** Thank you! We’re excited as well and appreciate your interest in our work.
